

Brazilian Journal of Global Health Revista Brasileira de Saúde Global

Physical exercise, body composition, cholesterol, and triglycerides in the HIV patient: a meta-analysis

Renan Germano¹, Gustavo C. Fernandes¹, Tabatah H. G. Santos², Luiz H. S. Nali³, Carolina N. França³, Lucas M, Neves^{1, 3, 4}

¹Especialista em Treinamento de força - Escola de Educação Física e Esporte da Universidade de São Paulo - Laboratório de treinamento de força. ² Graduanda em Educação Física - Universidade Santo Amaro - Unisa. ³Docente Mestrado em Ciências da Saúde - Universidade Santo Amaro - Unisa.⁴ Pesquisador do Programa de Transtorno Bipolar (PROMAN) do Instituto de Psiquiatria do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo - Ipq - HCUSP.

ABSTRACT

OBJECTIVE

To verify if the physical exercise is effective for improving body composition, total cholesterol and triglycerides in HIV patients.

METHODS

The present study is a systematic review with meta-analysis in order to investigate the effects of strength and / or aerobic exercise programs on HIV-positive individuals on body composition, total cholesterol and triglycerides. It is registered on the PROS-PERO platform (International prospective register of systematic reviews) under number CRD42016043451. The PICOS research strategy was adopted, selecting the main MeSH terms for the search on Embase, Pubmed and Web of Science platforms. The results were tabulated, selected according to their relevance and classified in relation to the risk of bias.

RESULTS

10 studies were selected. Although several studies individually pointed to the improvement in the investigated variables, meta-analytical statistics did not show significance for the variables of body composition (body and visceral fat, BMI, WHR, lean mass) and total cholesterol, but in the triglycerides variable there was a significant change with a large effect size (TE) (TE1.36 [0.28, 2.44].

CONCLUSIONS

The strength exercise and the aerobic exercise, performed in an isolated or combined are effective for significantly improving the triglycerides variable in patients with the HIV virus under the treatment of highly active antiretroviral therapies.

DESCRIPTORS

Resistance training. Anthropometry. Immune system. Acquired immunodeficiency syndrome.

Corresponding author:

Lucas Melo Neves Universidade de Santo Amaro, Universidade de Santo Amaro - Campus I. Sala Mestrado Ciências da Saúde - Prédio F1 Rua Professor Enéas de Siqueira Neto, 340 Jardim das Imbuias 04829300 - São Paulo, SP - Brasil E-mail: <u>Imneves@prof.unisa.br</u> ORCID ID: 0000-0003-2426-9736 **Copyright:** This is an open-access article distributed under the terms of the Creative Commons

Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided that the original author and source are credited.

DOI: https://doi.org/10.56242/globalhealth;2020;1;1;35-41



INTRODUCTION

The human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) is a serious public health challenge worldwide, despite widespread efforts to control the disease¹. In the absence of a cure currently, treatment is carried out with antiretroviral therapy - ART (antiretroviral therapy, from English - ART)² and highly active antiretroviral therapy (from English - HAART)³, which have prolonged the lives of carriers of the virus.

As a result of these therapies, changes in body composition and metabolic disorders of patients with HIV undergoing drug treatment are common⁴⁻⁶, such as generalized obesity and changes in the distribution of body fat⁷, dyslipidemia8 and lipodystrophy⁹. Such changes are associated with the risk of cardiovascular events^{8,10}, since the increase in visceral adipocytes is important in determining aspects relevant to health, such as obesity and overweight, highlighting the visceral adipose tissue as an important factor in increasing blood pressure, heart attack myocardium and insulin resistance¹¹.

Due to this problem, a strategy to avoid the increase of such adipocytes is to perform physical exercise, such as aerobic exercises that can contribute to the reduction of central and trunk fat¹², improving insulin sensitivity and dyslipidemia¹³, strength exercises, that can increase lean mass, promote weight gain and muscle strength¹⁴. In addition, the combination of both (strength training and aerobic), indicate improvements in physical fitness and other health indicators¹⁵.

Lindegaard et al¹⁶ verified the effects of physical exercise in HIV patients, pointing to an increase in lean mass and a decrease in body fat, in addition to improvements in the lipid profile. However, Terry et al¹⁷ detected improvements in body composition, but without significant differences for the lipid profile. Dolan and collaborators¹⁸, when evaluating the body composition and lipid profile of 40 HIV female patients, did not detect improvements in body composition after a physical exercise program. Thus, there is no consensus on the effectiveness of exercise in improving body composition in patients with HIV undergoing antiretroviral treatment.

Given the above, the present study aims to verify in the scientific literature the effects of aerobic or strength exercise programs isolated or combined on body composition. In addition, verifying changes in the variables total cholesterol and triglycerides are also objectives of this study. Our hypothesis is that exercise programs will be effective in reducing body fat, total cholesterol, and triglycerides.

METHODOS

Systematic search record

This research was registered in the International prospective register of systematic reviews, PROSPERO platform, under number CRD42016043451: <u>https://www.crd.york.ac.uk/</u> prospero/display_record.php?ID=CRD42016043451.

Eligibility criteria

The studies were eligible for inclusion in this meta-analysis if they met the following criteria: a) HIV patients undergoing drug treatment undergoing ongoing ART (antiretroviral therapy) or HAART (highly active antiretroviral therapy); b) Randomized clinical trials (RCTs) with more than 4 weeks of duration, investigating the effect of isolated or combined aerobic or strength physical exercises (concurrent training); c) body composition measures [total body fat, visceral fat, total lean mass, body mass index (BMI), waist circumference (WC), hip circumference (QC) and waist-to-hip ratio (WHR)] before and after the intervention. In addition, measures of total cholesterol or triglycerides were also analyzed; d) include a non-active control group, such as usual care / usual treatment, control conditions on the waiting list, placebo pills, other social activities without physical exercises; and in peer-reviewed journals in English.

Sources of information and research

The following databases were used: Embase, PubMed and Web of Science and the period of publication adopted was between January 2006 and December 2015.

Search

The 3-step model of evidence-based medicine was adopted for the search: formulation of a clinical question, search for evidence and evaluation of the same 19. Then, the search was structured considering the PICOS strategy, which consists of subdividing the study question into the following domains: population (P), intervention (I), control or comparison (C), outcomes or variables (O) and type of study (S), forming the acronym PICOS. In this way, individual searches for these domains are carried out, concatenating them in a final search with the Boolean operator "AND". English subject terms (medical subject headings - MeSH terms) were selected on the MeSH platform (http://www.ncbi.nlm.nih.gov/mesh) as described below. MeSH is the dictionary of vocabularies and synonyms controlled by NLM, used for indexing articles for PubMed. P: acquired immune deficiency syndrome OR acquired immuno-deficiency syndrome OR acquired immuno deficiency syndrome OR acquired immuno-deficiency syndromes OR aids OR human immunodeficiency virus OR human immunodeficiency virus, human OR immunodeficiency viruses, human OR virus, human immunodeficiency OR aids virus OR aids viruses OR virus, AIDS OR hiv; I: strength training OR resistance training OR weight training OR progressive training OR progressive resistance OR aerobic exercise OR aerobic training OR endurance exercise OR endurance training OR cardio training OR cardio exercise OR physical endurance OR physical exercise OR physical exertion OR exercises, physical; C: not used in the present study, aiming at a wider range of searches, not discarding articles with or without some type of comparison. O: fat body OR fat body composition OR body weight OR trunk fat OR visceral fat OR dexa OR abdominal fat OR regional adiposity OR adipose tissue OR fat tissue OR body fat distribution OR distribution, body fat OR fat loss OR weight loss; S: allocation, random OR randomization OR clinical trials, randomized OR randomized clinical trial OR randomized controlled study.

Analysis of the quality of clinical trials and risk of bias in each study

To assess the methodological quality of the studies, we adopted the modified Jadad scale²⁰, which assigns 1 point to the study description, blinding and loss and exclusion report fields, in addition to 1 additional point for the fields that assess whether the method it was adequate. Studies with a low methodological quality are classified as scoring less than 2 points in total. To analyze the risk of bias in each study, the Cochrane Collaboration tool²¹ was used, where the studies are critically evaluated in 7 domains by the authors for different aspects of the risk of bias²².

Selection of studies

After removing duplicates from different databases, the authors (RG and GC) selected all potentially eligible articles



based on titles and abstracts. After obtaining the full texts, the authors applied the eligibility criteria. If there was no consensus, the third author (LMN) evaluated the case and defined its inclusion / exclusion. In all studies, they extracted the number of subjects, the mean and standard deviations of the experimental and control groups to calculate the effect size (ES), standard error of the ES, lower confidence limit for ES, upper confidence limit for ES, Study weight and Study sample size.


Statistical analysis

All analyzes were conducted using the Comprehensive Meta-analysis software version 2.2 (Biostat Inc., Englewood, NJ, USA). Based on the results, the data were analyzed using random-effect models. The interpretation of the effect size (TE) was: 0 to <0.30 | small, |> 0.30 | for |<0.8 | average and |> 0.80 | wide.

RESULTS

Selection of studies

Below is presented the process of identification, extraction, and selection of studies through the flowchart Consort²³.



Flowchart 1. CONSORT flowchart with systematic selection of studies.

In the initial search, 197 potentially relevant articles were identified. After removing duplicates (31 articles), our research identified 166 potentially relevant articles. Of the remaining 166 articles, 64 studies published before 2006 were excluded. Thus, 102 articles in the full text review stage were accessed, with 92 studies being excluded [samples without HIV (n = 65); studies without exercise as an intervention (n = 13); Uncontrolled or randomized studies (n = 14). Thus, 10 complete peer-reviewed studies that met the eligibility criteria were included in our meta-analysis (16-18, 24-30).

Methodological quality

Table 1 and Figure 1 show the selected studies compiled regarding their methodological quality and their risk of bias, respectively, and classifies aspects of the experimental design

of the studies considering: low, uncertain, or high risk of bias.

Table 1. Studies compiled regarding methodological quality and risk of bias.

Study	Was the study described as random? (use of words such as random, random, randomization)	The method was adequate?	The study was described as double- blind?	The method was adequate?	There was a description of losses and exclusions?	TOTAL	
Terry L, et al., 2006	Yed					2	
		No	No	No	Yes		
Mitimura E, et al.,2008	Yes					2	
Mitimura E, et al.,2008b	Yes	No	No	No	Yes	2	
Balasubramanyan A, et al., 2011	Yes	No	No	No	Yes	5	
Ogalha C, et al.,2011	Yes	Yes	Yes	Yes	Yes	2	
Yarasheski KEC, et al.,2011	Yes	No	No	No	Yes	3	
Roos RM, et al., 2014	Yes	Yes	No	No	Yes	4	
Dolan SE, et al.2006	Yes	Yes	No	Yes	Yes	3	
Hamid M, et al.,2015	Yes	Yes	No	No	Yes	3	

Adapted from Jadad²⁰.




Figure 1. Assessment of the risk of bias in the studies presented by the authors and their respective results.

Table 2 shows the studies of interest compiled regarding the sample (number of subjects and percentage of women), type of intervention (type of training performed in the intervention group, intervention weeks and activities developed by the control group), synthesis of the tests performed (cholesterol and fraction measurements, and body composition - waist and hip circumference and waist-to-hip ratio, BMI, fat percentage, lean mass, and their results.

Table 2. Studies of interest compiled regarding the sample, interventions, tests performed, pre and post values, percentage o f change Total sample (N); standard deviation (sd); measured through skinfolds (CD); measured by dual emission X-ray absorptiometry (DEXA); measured through bioimpedance (BI); maximum oxygen consumption (VO2max); maximum beats per minute (max bpm); weeks.

Authors	N % woma n	Age (dp)	Intervention	Variables analyzed	Pre control group	Post control group	%Δ	Pre exercise group	Post exercise group	%Δ
				Cholesterol	256	251	-2,0	256	243	-5,1
	30	37,5	Experimental: diet + exercise - low fat + 12 wk. aerobic exercise	Body fat (DC)	23	19	- 17,4	27	22	-18,5
al, 2006	(30)	2,1	Control: diet - low fat + 12 wk. stretching	BMI RCQ Triglycerides Cholesterol	24 0,94 338 220	23 0,91 346 219,6	-4.2 -3.2 2.4 -0.2	25 0,91 325 229,3	24 0,90 296 223,5	-4.0 -1,1 -8,9 -2,5
Lindegaard 18 B, et al, (0)			Experimental: aerobic training: 16 weeks, 3x weeks, interval (35 min,	Body fat (DEXA)	18,6	15,3	17.7	19,5	18,5	-5,1
	49,5 (5,1)	Duration), intensities between 50 - 100% VO2max.	Lean mass Triglycerides	77,5	79,3	2,3	76,4	77	0,8	
2008	(0)	(0,1)	Control: strength training: 16 weeks, 3x weeks, 8 exercises (12 - 8 reps / 50% - 80% / 1-2 min. Interval		186	152,3	- 18,1	212,5	212,6	0,0
Mutimura E, 97 et al.2008 ^a (60)		37,7	Experimental: aerobic + strength: 6 months, 3x sem., 1.5 hours per	Circ. Waist Circ. Hip Cholesterol	83.1 93.7 150,4	83.8 93.9 152,7	0.8 0.2 1.5	91 92,3 146,1	83.8 93,4 147,3	-7.9 1,2 0,8
	(0,2)	training, stretching, 15 min. walking + 45 - 60 min. jogging and running	Body fat (DC)	29,3	29,1	-0,7	29,4	27,9	-5,1	
			(45% - 75% bpm max), climbing, lumbar and abdomen stabilization.	BMI	24,4	24,5	0,4	24	23,4 86,6	-2,5 5,5
			Control: without performing exercises	RCQ Trigriceridae	0,98 118,6	0,98 124,9	0,0 5,3	0,99 117,8	0,89 98,3	-10,1
				Circ. Waist Circ. Hip Body fat	92 93.7	92.3 93.9	0.3 0,2	91 92,3	83.9 93.4	-7.8 1,2
			Experimental: aerobic + strength: 6 months, 3x sem., 1.5 hours per		29,3	29,1	-0,7	29,4	27,9	-5,1
	100 (100)	37,7 (0,2)	training, stretching, 15 min of walking + 45 - 60 min jogging and running (45% - 75% bpm max), climbing, lumbar and weight stabilization abdomen. Control: without performing exercises	BMI	24,5	24,6	0,4	24	23,4	-2,5
			Experimental: diet + exercise +	Cholesterol	214.4	195,6	-8,8	207.9	178,4	-14.2
Balasubram anyan A, et	97	37,7	medication - weight maintenance diet + aerobic exercise programs + strength, 3x wk. lasting between 75 -	BMI Triglycerides	26,3	26,9	2,3	27,2	44,8 26,7	11,7 -1,8
anyan A, et (60) al. 2011	(60)	(0,2)	90 min. Control: guidance on healthy diet, 1 week food diary with later feedback and a guide on general exercises.		313,5	199	36,5	283,1	135,6	-52,1



			stret	tching	: nutr	itiona	l mor	strength hitoring a	ind Redu (et (DC)	78.7 189,8 20.1	78 186,8	-0.9 -1.6	82.0 222,72	80.8 203,7 19.9	-1. -8,
Ogalha C,	63	43,1		wit	thout.	for 2	4 we	d gym, 3 eks.	DMI	20,1	21,5 22,7	7,0 -1,3	21,5 22,9	19,9 22,3	-7, -2,
et al. 2011	(43)	0,7		ntrol: 1	1 mor	th of	work	shops wi	Loon moon	54.2 0,85	56	-1,3 3,3 -1,2	56,6	59,7	-2. 5.0 1,2
					al act	ivity a	nd n	utritional	7 RCQ Triglycerides	0,85 187.4	0,84	-1,2 9.0	0,84 190.2	0.85	1,2 -9,
					g	uidan	ce.		Circ. waist	187,4	204,3	-0.1	190,2	81.6	-9,
										00	10.0	-0.1	01	01.0	0.
									Hip Circ						
			Ex	perim	ental	aerć	bio: 1	12 meses	8.	103,5	103	-0,5	104,2	104,7	0,9
			carr					leradas, :	30 Cholesterol	168.2	160.1	-4.8	166.6	165.9	-0
Roos RM, 84 et al. 2014 (79)		39,1 9.6	min., 3 - 5 x por sem. Controle: apoio clínico e			BMI	25.4	26.8	5.5	25.8	58,3	6			
	-,-	monitoramento mensal sobre			BCO	0,77	0,77	0.0	0.78	27.4 89.7 0.77	-5. -1.				
				co	ondiçi	ões d	e saú	ide.	Triglycerides						
										90,3	93	3,0	86,7	88,5	2,
									Circ. Waist	99	100	1,0	103,8	103	-0.
									Cholesterol	162	162	0,0	191	189	-1,
Dolan SE.	40	41.5	Exp	erime teks	ntal: a 48 se	aerob ssion	ic + s s. 2 ⊦	strength: nours. pe	16 Body fat r (DEXA)	27,8	27,1	-2,5	28,7	28,5	-0
et al. 2006	(100)	2,1			s	essio	n.			111	119	7.2	142	140	-1
			Cont	ról: w	nout	perfo	ormin	g exercis	BMI	28.6	28.5	-0.3	29.3	51 29,7	-1
									Triglycerides	107	107	-0,3	141	109 147	1. -2 4
									Body fat (BI)						
Hamid M, et	29	41,7	Exp	perime	ental: with 1	12 w There	eeks, -Ban	, exercise d.	98	20,5	21,1	2,9	17,4	16,9	-2,
al. 2015	(0)	6,2	Cont	trol: 1	2 with	iout, :	simila	ar exercis	ses Lean mass	79,9	79,3	-0,8	82,6	83,1	0,
				w	ithout	ine	a-Ba	m0.		18,4	18,3	-0,5	19	19,7	3,
			Exp	perim	ental:	aero	bic +	strength	+ вмі	189.5	177.9	-6.1	181.7	174	-4
Yarasheski	39	45		med	dicatio	on - 4	mon	ths of n with 1.5	Divit	27,3	27,9	2,2	26,5	25,6	-3
KEC, et al. 2011	(100)	(1,4)	2h. (of exe	ercise	s per	day,	3x witho	ut. f Cholesterol	1,93	2	3,6	1,9	1,75	-7.
				JULU		glitaz		nonuns o	Body fat Visceral fat		-	-,-	.,	.,	2.
									enocerar lat	72,7 203,7	72,1 221,4	-0,8	73,5 186	74.4 159.4	-0. 1.3 -14
			ntrole			rcício			td. Mean Difference		Std. Mean Dif				
udy or Subgroup E. Dolan, et al. 2 Terry, et al. 2006	006	Mean 27.1 19	SD T 0.7 10	iotal 19 15		SD 1 0.4 10	fotal 19 15	Si Weight 12.2% 12.4%	td. Mean Difference IV, Random, 95% Cl -2.40 [-3.26, -1.55] -0.29 [-1.01, 0.43]		Std. Mean Dif IV, Random,				
E. Dolan, et al. 2 Terry, et al. 2006 galha, et al. 2011	006	Mean 27.1 19 21.5	SD T 0.7 10 13.8	19 15 28	28.5 22 20	SD 1 0.4 10 7	19 15 35	Weight 12.2% 12.4% 12.8%	V, Random, 95% Cl -2.40 [-3.26, -1.55] -0.29 [-1.01, 0.43] 0.14 [-0.36, 0.64]						
E. Dolan, et al. 2 Terry, et al. 2006 galha, et al. 2011 timura, et al. 200	006 8a	Mean 27.1 19 21.5 29.1	SD T 0.7 10 13.8 0.7	19 15 28 49	28.5 22 20 27.9	SD 1 0.4 10 7 3	19 15 35 48	Weight 12.2% 12.4% 12.8% 13.0%	N, Random, 95% Cl -2.40 [-3.26, -1.55] -0.29 [-1.01, 0.43] 0.14 [-0.36, 0.64] 0.55 [0.14, 0.95]						
E. Dolan, et al. 2 Terry, et al. 2006 galha, et al. 2011 timura, et al. 200 S. A. R. Hamid, e	006 8a et al. 2015	Mean 27.1 19 21.5	SD T 0.7 10 13.8	19 15 28	28.5 22 20	SD 1 0.4 10 7	19 15 35	Weight 12.2% 12.4% 12.8%	IV, Random, 95% CI -2.40 [-3.26, -1.55] -0.29 [-1.01, 0.43] 0.14 [-0.36, 0.64] 0.55 [0.14, 0.95] 0.62 [-0.31, 1.55]					_	
E. Dolan, et al. 2 Terry, et al. 2006 galha, et al. 2011 timura, et al. 200 S. A. R. Hamid, e E. C. Yarasheski alasubramanyan,	006 8a et al. 2015 i, et al. 2011 , et al. 2011	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1	SD 1 0.7 10 13.8 0.7 2.9 2.6 1.1	19 15 28 49 9 20 26	Mean 28.5 22 20 27.9 9 22.6 22.3	SD 1 0.4 10 7 3 2 2 1	19 15 35 48 10 19 28	Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 12.5%	N, Random, 95% Cl -2.40 [-3.26, -1.55] -0.29 [-1.01, 0.43] 0.14 [-0.36, 0.64] 0.55 [0.14, 0.95] 0.62 [-0.31, 1.55] 1.14 [0.45, 1.82] 1.69 [1.06, 2.32]				1		
E. Dolan, et al. 2 Terry, et al. 2006 galha, et al. 2011 timura, et al. 200 S.A.R. Hamid, e E.C. Yarasheski	006 8a et al. 2015 i, et al. 2011 , et al. 2011	Mean 27.1 19 21.5 29.1 10.6 25.3	SD 1 0.7 10 13.8 0.7 2.9 2.6	19 15 28 49 9 20	Mean 28.5 22 20 27.9 9 22.6	SD 1 0.4 10 7 3 2 2	19 15 35 48 10 19	Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5%	IV, Random, 95% Cl -2.40 [-3.26, -1.55] -0.29 [-1.01, 0.43] 0.14 [-0.36, 0.64] 0.55 [0.14, 0.95] 0.62 [-0.31, 1.55] 1.14 [0.45, 1.82]				· -+		
E. Dolan, et al. 2 Terry, et al. 2006 galha, et al. 2011 timura, et al. 2010 S. A. R. Hamid, e E. C. Yarasheski alasubramanyan, timura, et al. 200 tal (99% CI)	006 8a et al. 2015 i, et al. 2011 et al. 2011 8b	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1 19.2	SD 1 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3	19 15 28 49 9 20 26 49 215	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6	SD 1 0.4 10 7 3 2 2 1 1	19 15 35 48 10 19 28 48 222	Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 12.5%	N, Random, 95% Cl -2.40 [-3.26, -1.55] -0.29 [-1.01, 0.43] 0.14 [-0.36, 0.64] 0.55 [0.14, 0.95] 0.62 [-0.31, 1.55] 1.14 [0.45, 1.82] 1.69 [1.06, 2.32]				_		
E. Dolan, et al. 20 Terry, et al. 2006 galha, et al. 2011 timura, et al. 2010 S. A. R. Hamild, et E. C. Yarasheski alasubramarryan, timura, et al. 200 tal (99% CI) aterogeneity. Tau'	006 8a et al. 2015 i, et al. 2011 , et al. 2011 8b ² = 2.21; Ch≓	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1 19.2 = 158.39	SD 1 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3	19 15 28 49 9 20 26 49 215	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6	SD 1 0.4 10 7 3 2 2 1 1	19 15 35 48 10 19 28 48 222	Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 12.5% 12.5%	M, Random, 95% Cl -2.40 [-3.26, -1.55] -0.28 [-1.01, 0.43] 0.45 [0.14, 0.95] 0.62 [-0.31, 1.55] 1.14 [0.45, 1.82] 1.69 [1.06, 2.32] 3.93 [3.24, 4.62]		IV, Random,				
E. Dolan, et al. 2 Terry, et al. 2006 galha, et al. 2011 timura, et al. 2010 S. A. R. Hamid, e E. C. Yarasheski alasubramanyan, timura, et al. 200 tal (99% CI)	006 8a et al. 2015 i, et al. 2011 , et al. 2011 8b ² = 2.21; Ch≓	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1 19.2 = 158.39	SD 1 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3	19 15 28 49 9 20 26 49 215	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6	SD 1 0.4 10 7 3 2 2 1 1	19 15 35 48 10 19 28 48 222	Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 12.5% 12.5%	M, Random, 95% Cl -2.40 [-3.26, -1.55] -0.28 [-1.01, 0.43] 0.45 [0.14, 0.95] 0.62 [-0.31, 1.55] 1.14 [0.45, 1.82] 1.69 [1.06, 2.32] 3.93 [3.24, 4.62]		IV, Random,	95% CI		_	
E. Dolan, et al. 20 Terry, et al. 2006 galha, et al. 2011 timura, et al. 2010 S. A. R. Hamild, et E. C. Yarasheski alasubramarryan, timura, et al. 200 tal (99% CI) aterogeneity. Tau'	006 8a et al. 2015 i, et al. 2011 , et al. 2011 8b ² = 2.21; Ch≓	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1 19.2 = 158.39	SD 1 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3	19 15 28 49 9 20 26 49 215	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6	SD 1 0.4 10 7 3 2 2 1 1	19 15 35 48 10 19 28 48 222	Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 12.5% 12.5%	M, Random, 95% Cl -2.40 [-3.26, -1.55] -0.28 [-1.01, 0.43] 0.45 [0.14, 0.95] 0.62 [-0.31, 1.55] 1.14 [0.45, 1.82] 1.69 [1.06, 2.32] 3.93 [3.24, 4.62]		1V, Random,	95% CI	4 perimental)	-	A
E. Dolan, et al. 20 Terry, et al. 2006 galha, et al. 2011 timura, et al. 2010 S. A. R. Hamild, et E. C. Yarasheski alasubramarryan, timura, et al. 200 tal (99% CI) aterogeneity. Tau'	006 8a et al. 2015 i, et al. 2011 , et al. 2011 8b ² = 2.21; Ch≓	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1 19.2 = 158.39	SD 1 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3	19 15 28 49 9 20 26 49 215	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6	SD 1 0.4 10 7 3 2 2 1 1	19 15 35 48 10 19 28 48 222	Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 12.5% 12.5%	M, Random, 95% Cl -2.40 [-3.26, -1.55] -0.28 [-1.01, 0.43] 0.45 [0.14, 0.95] 0.62 [-0.31, 1.55] 1.14 [0.45, 1.82] 1.69 [1.06, 2.32] 3.93 [3.24, 4.62]		1V, Random,	95% CI		-	Α
E. Dolan, et al. 20 Terry, et al. 2006 galha, et al. 2011 timura, et al. 2010 S. A. R. Hamild, et E. C. Yarasheski alasubramarryan, timura, et al. 200 tal (99% CI) aterogeneity. Tau'	006 8a et al. 2015 i, et al. 2011 , et al. 2011 8b ² = 2.21; Ch≓	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1 19.2 = 158.39	SD 1 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3	19 15 28 49 9 20 26 49 215	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6	SD 1 0.4 10 7 3 2 2 1 1	19 15 35 48 10 19 28 48 222	Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 12.5% 12.5%	M, Random, 95% Cl -2.40 [-3.26, -1.55] -0.28 [-1.01, 0.43] 0.45 [0.14, 0.95] 0.62 [-0.31, 1.55] 1.14 [0.45, 1.82] 1.69 [1.06, 2.32] 3.93 [3.24, 4.62]		1V, Random,	95% CI	4 berimental]	_	A
E. Dolan, et al. 20 Terry, et al. 2006 galha, et al. 2011 timura, et al. 2010 S. A. R. Hamild, et E. C. Yarasheski alasubramarryan, timura, et al. 200 tal (99% CI) aterogeneity. Tau'	006 8a et al. 2015 i, et al. 2011 , et al. 2011 8b ² = 2.21; Ch≓	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1 19.2 = 158.39 = 0.21)	SD T 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3 1.3	19 15 28 49 9 20 26 49 215	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6	<u>SD 1</u> 10 7 3 2 2 1 1 1 ; P =9	19 15 35 48 10 19 28 48 222	Weight 12.2% 12.4% 12.8% 12.0% 12.5% 12.6% 12.5% 100.0%	M. Random, 95% C -2.019;10(1,043) 0.04(1036,064) 0.55(014,036) 0.55(014,036) 0.62(021,155) 1.44(045,182) 1.44(045,182) 1.46(106,232) 3.83(324,462) 0.68(0.77,2.07)		V, Random,	95% CI		-	A
E Dolan, et al. 22 Terry, et al. 2006 ganha, et al. 2010 S. A. R. Harnid, et al. 2000 S. A. R. Harnid, et al. 2000 E. C. Yarasheshe La C. Yarasheshe La C. Yarasheshe La C. Yarasheshe Van St. Charlow Charles C. Charlow Char	006 8a 2t al. 2015 1, et al. 2011 8b ² = 2.21; Chi ^a ct Z = 1.26 (f	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1 19.2 = 158.39 = 0.21)	SD T 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3 , df = 7 () 0	19 15 28 49 9 20 26 49 215 P < 0.0	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6	SD 1 0.4 10 7 3 2 2 1 1 ; F=9 9	19 15 35 48 10 19 28 48 222 5%	Weight 12.2% 12.4% 12.8% 13.0% 12.5% 12.5% 100.0% St	M. Random, 95% C 2.40 (1-32, 4-15) -0.23 (1-10), 0.43 (1-4) (0.35, 0.64) 0.55 (0.14, 0.95) 0.65 (0.14, 0.95) 0.65 (0.14, 0.95) 0.65 (0.14, 0.95) 0.65 (0.14, 0.95) 1.14 (0.62, 1.62) 1.69 (1.06, 2.32) 3.93 (3.24, 4.62) 0.688 [0.71, 2.07]	Farour	IV, Random,	95% CI		-	A
E. Dolan, et al. 20 Terry, et al. 2006 janha, et al. 2010 S. A. R. Hamild, et E. C. Yarasheek Laisubramanyan, Imura, et al. 200 teal (99% CI) terrogeneht, Tatis st for overall effe	006 8a et al. 2015 (, et al. 2011 8b ² = 2.21; Chii ⁿ ct Z = 1.26 (F pp pp kil, et al. 2011	Mean 27.1 19 21.5 29.1 106 25.3 24.1 19.2 = 158.39 >= 0.21)	SD T 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3 ., df = 7 ()	19 15 28 49 9 20 26 49 20 26 49 215 P < 0.0	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6 100001) 00001)	SD 1 0.4 10 7 3 2 2 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 1 1 2 2 2 1 1	19 15 35 48 10 19 28 48 222 5%	Weight 12.2% 12.4% 12.8% 12.0% 12.6% 12.5% 100.0% SI Weight 33.1%	M. Random, 95% Cl 2.40 (5.28, 1.55) -0.29 (1-01, 0.43) 0.4 (1-03, 0.64) 0.55 (1-4, 0.95) 0.62 (1-03, 1.55) 1.44 (10.45, 1.62) 1.69 (10.6, 2.22) 3.93 (3.24, 4.52) 0.68 (0.71, 2.07) 	Farour	V, Random,	95% CI	4 perimental]	_	A
E. Dolan, et al. 2 Terry, et al. 2006 Janha, et al. 2011 Immura, et al. 2005 S. A. R. Hamid, et al. 2005 S. A. R. Hamid, et al. 2005 Immura, et al	8a tal 2015 i, et al. 2015 et al. 2011 8b ² = 2.21; Chi ^a ct Z = 1.26 (f pp pp kil, et al. 2011 1	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1 19.2 = 158.39 >= 0.21) End Mean 65.6 59.6	SD I 0.7 10 13.8 0.7 2.6 1.1 1.3 2.6 1.1 1.3	19 15 28 49 9 20 26 49 20 26 49 20 26 49 20 26 49 20 26 49 19 35	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6 100001) 00001) Com Mean 65.3 56	SD 1 0.4 10 7 3 2 2 1 1 1 1 (F = 9) 1 strole SD 1 2.2 1 1	19 15 35 48 10 19 28 48 222 6%	Weight 12.2% 12.4% 12.8% 12.0% 12.5% 12.5% 100.0% St Weight 33.1% 52.0%	M, Random, 95% Cl 240 (5:28, 1-55) -0.29 (1:01, 0.43) 0.14 (1:03, 0.64) 0.62 (1:01, 1:05) 1.64 (1:06, 2:23) 3.93 (3:24, 4:62) 0.68 [0.71, 2:67] 0.68 [0.71, 2:67] 	Farour	IV, Random,	95% CI	4 perimental]	-	A
E. Dolan, et al. 2 Terry, et al. 2006 Jana, et al. 2011 Immure, et al. 2008 S. A. F. Harrid, et al. 2008 S. A. F. Harrid, et al. 2007 Immure, et al. 2007 Interception of the state of the state Interception of the state of the state Study of Subgroup Study of Subgroup Study of Subgroup	8a tal 2015 i, et al. 2015 et al. 2011 8b ² = 2.21; Chi ^a ct Z = 1.26 (f pp pp kil, et al. 2011 1	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1 19.2 = 158.39 >= 0.21) End Mean 65.6 59.6	SD T 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3 ., df = 7 ()	19 15 28 49 9 20 26 49 215 P < 0.0	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6 100001) 100001)	SD 1 0.4 10 7 3 2 2 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 1 1 2 2 2 1 1	19 15 35 48 10 19 28 48 222 6% 6%	Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 100.0% \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	M, Random, 95% Cl 240(5):28, 1-55) -0.29(1+0), 0.43 0.14(-0.38, 0.64) 0.52(-0.31, 1-55) 1.44(-0.53, 0.64) 0.52(-0.31, 1-55) 1.44(-0.54, 1-52) 1.64(10, 62, 2-22) 3.93(3):24, 4.62] 0.68(10.74, 2.07) 	Farour	IV, Random,	95% CI	4 perimental]	-	A
E Dolan, et al. 21 Terry, et al. 2006 Jana, et al. 2011 Immura, et al. 2008 S. A. R. Harrid, et al. 2008 S. A. R. Harrid, et al. 2008 Study or Subgroup et al. 2009 CO et a	006 8a tal. 2015 , et al. 2011 8b *= 2.21; Chi ^a ct Z = 1.26 (f kii, et al. 2011 1 et al. 2015	Mean 27.1 19 29.1 10.6 25.3 24.1 19.2 = 158.399 = = 0.21) Mean % Mean	SD I 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3	19 15 28 49 9 20 26 49 215 P < 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6 100001) Com Mean 65.3 56 38.8	SD 1 0.4 10 7 3 2 2 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 1 1 2 2 1 1 1 1 2 1 1 2 2 1 1 2 2 1 1 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 2 2 <td>19 15 35 48 10 19 28 48 222 6% 6%</td> <td>Weight 12.2% 12.4% 12.8% 12.0% 12.5% 12.5% 100.0% St Weight 33.1% 52.0%</td> <td>M. Random, 95% Cl 2.40 (5.28, 1.55) -0.29 (1.01, 0.43) 0.14 (1.03, 0.64) 0.52 (1.01, 0.53) 0.62 (1.01, 0.55) 0.62 (1.01, 0.55) 1.14 (1.045, 1.82) 1.69 (1.06, 2.32) 1.69 (1.06</td> <td>-4 -4 Farour</td> <td>IV, Random,</td> <td>95% CI</td> <td>4 perimental]</td> <td>_</td> <td>A</td>	19 15 35 48 10 19 28 48 222 6% 6%	Weight 12.2% 12.4% 12.8% 12.0% 12.5% 12.5% 100.0% St Weight 33.1% 52.0%	M. Random, 95% Cl 2.40 (5.28, 1.55) -0.29 (1.01, 0.43) 0.14 (1.03, 0.64) 0.52 (1.01, 0.53) 0.62 (1.01, 0.55) 0.62 (1.01, 0.55) 1.14 (1.045, 1.82) 1.69 (1.06, 2.32) 1.69 (1.06	-4 -4 Farour	IV, Random,	95% CI	4 perimental]	_	A
E. Dolan, et al. 2 Terry, et al. 2006 Jana, et al. 2011 Immure, et al. 2008 S. A. F. Harrid, et al. 2008 S. A. F. Harrid, et al. 2007 Immure, et al. 2007 Interception of the state of the state Interception of the state of the state Study of Subgroup Study of Subgroup Study of Subgroup	006 8a et al. 2015 (et al. 2011 8b ² = 2.21; Chi ^m ct. Z = 1.26 (F ² ki, et al. 2011 1 et al. 2015	Mean 27.1 19 29.1 10.6 25.3 24.1 19.2 19.2 24.1 19.2 19.2 24.1 19.2 24.1 19.2 24.1 19.2 0.20.1 Dependence Mean 65.6, 59.6 59.6, 59.9 44.3 P= 0.94, 42.3	SD I 0.7 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3	19 15 28 49 9 20 26 49 215 P < 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6 100001) Com Mean 65.3 56 38.8	SD 1 0.4 10 7 3 2 2 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 1 1 2 2 1 1 1 1 2 1 1 2 2 1 1 2 2 1 1 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 2 2 <td>19 15 35 48 10 19 28 48 222 6% 6%</td> <td>Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 100.0% \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$</td> <td>M, Random, 95% Cl 240(5):28, 1-55) -0.29(1+0), 0.43 0.14(-0.38, 0.64) 0.52(-0.31, 1-55) 1.44(-0.53, 0.64) 0.52(-0.31, 1-55) 1.44(-0.54, 1-52) 1.64(10, 62, 2-22) 3.93(3):24, 4.62] 0.68(10.74, 2.07) </td> <td>Favour</td> <td>N, Random,</td> <td>ference 95% CI</td> <td></td> <td>-</td> <td>A</td>	19 15 35 48 10 19 28 48 222 6% 6%	Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 100.0% \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	M, Random, 95% Cl 240(5):28, 1-55) -0.29(1+0), 0.43 0.14(-0.38, 0.64) 0.52(-0.31, 1-55) 1.44(-0.53, 0.64) 0.52(-0.31, 1-55) 1.44(-0.54, 1-52) 1.64(10, 62, 2-22) 3.93(3):24, 4.62] 0.68(10.74, 2.07) 	Favour	N, Random,	ference 95% CI		-	A
E Dolan, et al. 2 Eroy, et al. 2005 partia, et al. 2011 Immus, et al. 2001 Immus, et al. 2001 S. R. Hamid, Isauburamanyan, Immus, et al. 2000 tal (99% CI) Batedy or Subagrous Study or Subagrous Study or Subagrous Study or Subagrous Study of Subagrous S	006 8a et al. 2015 (et al. 2011 8b ² = 2.21; Chi ^m ct. Z = 1.26 (F ² ki, et al. 2011 1 et al. 2015	Mean 27.1 19 29.1 10.6 25.3 24.1 19.2 19.2 24.1 19.2 19.2 24.1 19.2 24.1 19.2 24.1 19.2 0.20.1 Dependence Mean 65.6, 59.6 59.6, 59.9 44.3 P= 0.94, 42.3	SD I 0.7 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3	19 15 28 49 9 20 26 49 215 P < 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6 100001) Com Mean 65.3 56 38.8	SD 1 0.4 10 7 3 2 2 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 1 1 2 1 1 1 1 1 2 1 1 2 2 1 1 2 2 1 1 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 2 2 <td>19 15 35 48 10 19 28 48 222 6% 6%</td> <td>Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 100.0% \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$</td> <td>M. Random, 95% Cl 2.40 (5.28, 1.55) -0.29 (1.01, 0.43) 0.14 (1.03, 0.64) 0.52 (1.01, 0.53) 0.62 (1.01, 0.55) 0.62 (1.01, 0.55) 1.14 (1.045, 1.82) 1.69 (1.06, 2.32) 1.69 (1.06</td> <td>Favour</td> <td>N, Random,</td> <td>ference 95% CI</td> <td></td> <td>- Tz</td> <td></td>	19 15 35 48 10 19 28 48 222 6% 6%	Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 100.0% \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	M. Random, 95% Cl 2.40 (5.28, 1.55) -0.29 (1.01, 0.43) 0.14 (1.03, 0.64) 0.52 (1.01, 0.53) 0.62 (1.01, 0.55) 0.62 (1.01, 0.55) 1.14 (1.045, 1.82) 1.69 (1.06, 2.32) 1.69 (1.06	Favour	N, Random,	ference 95% CI		- Tz	
E Dolan, et al. 2 Eroy, et al. 2005 partia, et al. 2011 Immus, et al. 2001 Immus, et al. 2001 S. R. Hamid, Isauburamanyan, Immus, et al. 2000 tal (99% CI) Batedy or Subagrous Study or Subagrous Study or Subagrous Study or Subagrous Study of Subagrous S	006 8a et al. 2015 (et al. 2011 8b ² = 2.21; Chi ^m ct. Z = 1.26 (F ² ki, et al. 2011 1 et al. 2015	Mean 27.1 19 29.1 10.6 25.3 24.1 19.2 19.2 24.1 19.2 19.2 24.1 19.2 24.1 19.2 24.1 19.2 0.20.1 Dependence Mean 65.6, 59.6 59.6, 59.9 44.3 P= 0.94, 42.3	SD I 0.7 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3	19 15 28 49 9 20 26 49 215 P < 0.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6 100001) Com Mean 65.3 56 38.8	SD 1 0.4 10 7 3 2 2 1 1 1 1 1 1 1 1 1 1 1 1 2 2 1 1 1 2 1 1 1 1 1 2 1 1 2 2 1 1 2 2 1 1 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 1 1 2 2 2 2 <td>19 15 35 48 10 19 28 48 222 6% 6%</td> <td>Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 100.0% \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$</td> <td>M. Random, 95% Cl 2.40 (5.28, 1.55) -0.29 (1.01, 0.43) 0.14 (1.03, 0.64) 0.52 (1.01, 0.53) 0.62 (1.01, 0.55) 0.62 (1.01, 0.55) 1.14 (1.045, 1.82) 1.69 (1.06, 2.32) 1.69 (1.06</td> <td>Favour</td> <td>N, Random,</td> <td>ference 95% CI</td> <td></td> <td>- Tr</td> <td></td>	19 15 35 48 10 19 28 48 222 6% 6%	Weight 12.2% 12.4% 12.8% 13.0% 12.0% 12.5% 100.0% \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	M. Random, 95% Cl 2.40 (5.28, 1.55) -0.29 (1.01, 0.43) 0.14 (1.03, 0.64) 0.52 (1.01, 0.53) 0.62 (1.01, 0.55) 0.62 (1.01, 0.55) 1.14 (1.045, 1.82) 1.69 (1.06, 2.32) 1.69 (1.06	Favour	N, Random,	ference 95% CI		- Tr	
E. Dolan, et al. 2 Error, et al. 2006 paha, et al. 2011 imurua, et al. 2001 imurua, et al. 2003 S. A. R. Harrid, et E. C. Yarashashishi lasubramanyan, et al. 2006 etal. 2006 etal. 2007 etal. 2007 et	0006 9a 4t al: 2015 et al: 2011 et al: 2011 9a 2 = 2: 21; Chi ² h et al: 2011 1 et al: 2015 1 et al: 2015 1 et al: 2015 2 et al: 2015 1 et al: 2015	Mean 27.1 19 21.5 29.1 106 25.3 24.1 19.2 = 158.39 >= 0.21) Es Mean 65.6 59.4 44.3 P= 0.94, (P= 0.06)	SD I 0.7 0.7 10 7 13.8 0.7 2.6 1.1 1.1 1.3	19 15 28 49 20 26 49 215 P < 0.0 215 P < 0.0 35 10 64 = 0.62	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6 100001) Com Mean 65.3 56 38.8 38.8	SD 1 0.4 10 7 3 2 1 1 1 <td>19 15 35 48 10 19 28 48 222 6% 6%</td> <td>Weight 12.2% 12.4% 12.8% 12.0% 12.0% 12.0% 12.0% 12.5% 12.5% 12.5% 100.0%</td> <td>M. Random, 95% Cl 240 (5:28, 1-55) -0.29 (1:01, 0.43) 0.14 (1:03, 0.64) 0.62 (1:01, 0.26) 0.62 (1:01, 0.55) 1.44 (0.45, 1.82) 1.64 (10, 62, 22) 3.93 (3:24, 4.62) 0.68 (0.71, 2.67) </td> <td>Favour Favours</td> <td>N, Random,</td> <td>ference</td> <td></td> <td>-</td> <td></td>	19 15 35 48 10 19 28 48 222 6% 6%	Weight 12.2% 12.4% 12.8% 12.0% 12.0% 12.0% 12.0% 12.5% 12.5% 12.5% 100.0%	M. Random, 95% Cl 240 (5:28, 1-55) -0.29 (1:01, 0.43) 0.14 (1:03, 0.64) 0.62 (1:01, 0.26) 0.62 (1:01, 0.55) 1.44 (0.45, 1.82) 1.64 (10, 62, 22) 3.93 (3:24, 4.62) 0.68 (0.71, 2.67) 	Favour Favours	N, Random,	ference		-	
E. Dolan, et al. 2 Error, et al. 2006 pana, et al. 2011 imura, et al. 2001 imura, et al. 2001 imura, et al. 2001 E. C. Yarasheels E. C. Yarasheels E. C. Yarasheel digosh. Ch. et al. 2006 et al. 2006 et al. 2007 et	0006 8a Hal 2015 et al 2015 et al 2011 et al 2011 86, et al 2011 86, et al 2011 1 et al 2015 et al 2011 et al 2015 et al 2011 et al 2015 et al	Mean 27.1 17.9 19.2 21.5 29.1 10.6 25.3 24.1 19.2 = 158.39 >= 0.21) Mean 65.6 59.6 9.2 0.21)	SD I I 0.7 0.7 10 7 13.8 0.7 2.9 1.1 1.3	19 15 15 28 49 9 20 26 49 9 215 P < 0.0	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6 14.6 100001) Com 65.3 56 38.8 38.8 1); P = 1 Esc. 40.5 22.3 14.6 100001)	SD 1 0.4 10 7 3 2 1 1 1 3 2 1 1 5D 1 2 1 1 1 2 2 1 1 2 2 10 7.5 0% 500 500 300	19 15 35 48 10 19 28 48 222 6% 57 57	Weight 12,2% 12,4% 12,8% 12,8% 12,0% 12,0% 12,0% 12,5% 100,0% \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	M. Random .95% Cl 2.40 (5.28, 1.55) -0.29 (1.01, 0.43) 0.4 (1.03, 0.64) 0.55 (1.41, 0.95) 0.62 (1.01, 1.55) 1.44 (1.045, 1.82) 1.69 (1.06, 2.32) 1.69 (1.06,	Favour Favours	V. Random, V. Random, Stit. Mean Dif (control) Fi	ference		72	
E. Dolan, et al. 2 Terry, et al. 2006 jana, et al. 2011 imurua; et al. 2001 imurua; et al. 2001 imurua; et al. 2004 imurua; et al. 2004 et al	88 at all 2015 ct all 2011 ct all 2012 ct	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1 19.2 = 158.39 >= 0.21) Mean 65.65 9.9 Mean 26 27.1 9.2 9.2 10.2	SD I T 0.7 10 10 10 13.8 0.7 2.9 2.6 1.1 1.3	19 15 28 49 20 26 49 20 26 49 215 P < 0.0	Mean 28.5 22 27.9 9 22.6 22.3 14.6 100001) Com Mean 65.3 56 38.8 2; 17.9 14.6 100001) Com Mean 65.7 26 27.9 14.6 1	SD 1 0.4 10 7 3 2 1 1 1 SD 1 1 1 SD 1 2 2 1 1 2 2 1 1 3 2 2 1 1 1 2 2 1 1 3 2 10 7.5 3% 3 0% 3 0% 3	19 15 35 48 10 19 28 48 222 5% 57 Total 29 57 Total	Weight 12.2% 12.4% 12.4% 12.8% 12.0% 12.0% 12.5% 12.5% 12.5% 100.0% \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$ \$	M. Random, 95% C1 2.40 (1-23, 4.55) -0.29 (1-01, 0.43) 0.41 (0.33, 0.64) 0.52 (0.11, 65) 1.41 (0.45, 1.63) 1.40 (10, 6.23) 1.69 (10, 6.	Favour Favours	V. Random, V. Random, Stit. Mean Dif (control) Fi	ference		72	
E. Dolan, et al. 2 Eron, et al. 2006 pana, et al. 2011 imurua; et al. 2001 imurua; et al. 2001 imurua; et al. 2001 imurua; et al. 2001 et al. 2007 et al.	9006 91 11 2015 11 2015 11 2015 11 2015 12 2015 1	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1 19.2 = 158.39 >= 0.21) E Mean 65.55.5 59.6 44.3 P= 0.94, 44.3 26.9 218.3 24.6 24.6 24.6	SD T T 0.7 10 10 10 13.8 0.7 2.9 2.6 1.1 1.3	19 15 28 49 20 26 49 20 26 49 215 P < 0.0	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6 100001) Com Mean 65.3 38.8 38.8 (); P = 1 55 38.8 (); P = 1 19.7 24.7 24.7 25.3 47.7 24.7 25.3 25.5 25.3 25.4 25.3 25.4 25.3 25.4 25.3 25.4 25.3 25.4 25.	SD 1 0.4 10 7 3 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	19 15 35 48 10 19 28 48 222 5% 5%	Weight 1228 1248 1248 1285 1205 1205 1205 1255 1255 100.05 52.05 150.05 150.05 12265 12265 12265 12265 12265	M. Random, 95% Cl 2.40 (1-23, 4.55) -0.29 (1-01, 0.43) 0.14 (1-03, 0.64) 0.52 (1-01, 1-05) 0.62 (1-01, 1-55) 1.44 (1-04, 5), 1-23 1.69 (1-06, 2-23) 3.93 (3-24, 4-52) 0.68 (0.71, 2.07) d. Mean Difference M. Random, 95% Cl 0.55 (0.04, 0.71) -2 2.54, Mean Difference M. Random, 95% Cl 0.55 (0.04, 0.71) -2 2.54, Mean Difference M. Random, 95% Cl 0.55 (0.04, 0.71) -2 2.54, Mean Difference M. Random, 95% Cl 0.55 (0.05, 0.07) -2 2.54, 0.55, 0.00 -0.54 (1-46, 0.27) -2 2.55, 0.00 -0.54 (1-46, 0.27) -2 2.54, 0.55, 0.00 -0.54 (1-46, 0.27) -2 2.54, 0.55, 0.00 -0.54 (1-46, 0.27) -2 2.54, 0.55, 0.00 -0.54 (1-46, 0.27) -2 2.54, 0.55, 0.00 -3, 0.54, 0.00, 0.71 -2 -2 -2 -2 -2 -2 -2 -2 -2 -2	Favour Favours	V. Random, V. Random, Stit. Mean Dif (control) Fi	ference			
E. Dolan, et al. 2 Erner, et al. 2006 pana, et al. 2011 imurua; et al. 2001 imurua; et al. 2001 imurua; et al. 2005 S. A. R. Hamid, et E. C. Yarasheels Le C. Yarasheels pana, et al. 2006 terogeneity: Tau' et al. 600 Study or Subgroup et al. 2007 imurua; et al. 2007 Study or Subgroup et al. 2007 Study of S	98 4 al 2015 (et al. 2014) 4 al 2015 (et al. 2015 al 2	Mean 27.1 19 21.5 29.1 10.6 25.3 24.1 19.2 = 158.39 >= 0.21) Mean 65.65 9.9 Mean 26 27.1 9.2 9.2 10.2	SD I T 0.7 10 13.8 0.7 2.9 2.6 1.1 1.3	19 15 28 49 9 20 26 49 9 20 215 P < 0.0	Mean 28.5 22 20 27.9 9 22.6 22.3 14.6 100001) Com Mean 65.3 56 38.8 38.8 37.9 14.6 14.7 14.6 14.7 1	SD 1 0.4 10 10 7 3 2 2 1 1 1 1 1 2 2 1 1 2 2 1 1 2 2 10 7.5 0% 30 0.75 3 2.7 1.2	19 15 35 48 10 19 28 48 222 6% 20 28 9 9 57 57	Weight 12.2% 12.4% 12.8% 12.0% 12.0% 12.0% 12.0% 12.5% 100.0% 52.0% 15.0% 15.0% 15.0% 15.0% 12.2% 12.2% 12.2% 12.2% 12.2%	M. Random, 95%; Cl 2.40 (5) 23, 4.55) -0.29 (1-01, 0, 4.3) -0.4 (-0.38, 0, 64) -0.55 (0, 14, 0, 95) -0.22 (-0.11, 55) -1.4 (-0.45, 1, 62) -0.62 (-0.11, 55) -1.4 (-0.45, 1, 62) -0.68 (-0.77, 2, 07) -0.55 (-0.40, 0, 77) -0.35 (-0.41, 53) -0.35 (-0.04, 0, 77) -0.35 (-0.41, 53) -0.35 (-0.04, 0, 77) -0.35 (-0.13, 0, 88) -0.35 (-0.04, 0, 77) -0.35 (-0.13, 0, 88) -0.35 (-0.04, 0, 77) -0.35 (-0.04, 0, 77) -0.35 (-0.13, 0, 80) -0.35 (-0.04, 0, 77) -0.35 (Favour Favours	V. Random, V. Random, Stit. Mean Dif (control) Fi	ference		72	




Figure 2. (Forest plot) Body composition variables - Figure 2A: Total body fat; Figure 2B: Lean Mass; Figure 2C: BMI; Figure 2D: Waist-hip ratio-CRQ.

All studies reported body composition variables, with 8 studies using total body fat as a variable (Figure 2A). Totaling 437 patients (215 patients in the control group and 222 patients in the intervention group), there was no significant difference between the groups [TE0.68 (CI: -0.71, 2.07)], with a heterogeneity of 96% (high).

Only 3 studies used lean mass as a variable (Figure 2B). Totaling 121 patients (64 patients in the control group and 57 in the intervention group), there was no significant difference between the interventions [TE0.35 (CI: -0.01, 0.71)], with a heterogeneity of 0% (low).

Eight studies were verified that used BMI as a variable (Figure 2C). Totaling 449 patients (217 patients in the control group and 232 patients in the intervention group), no significant difference was found between the interventions [TE 0.44 (Cl: -0.85, 1.72)], with a heterogeneity of 97% (high). Six studies were verified that used WHR as a variable (Figure 2D). Totaling 392 patients (189 patients in the control group and 203 patients in the intervention group), there was no significant difference between the interventions [TE 0.41 (CI: -0.11, 0.93)], with a heterogeneity of 84% (discharge).




Figure 3. (Forest plot). Variables total cholesterol (Figure 3A) and triglycerides (Figure 3B).

Five studies were found that used total cholesterol as a variable (Figure 3A). Totaling 245 patients (115 patients in the control group and 130 patients in the intervention group), no significant difference was found between the interventions [TE -0.05 (CI: -1.94, 1.84)], with a heterogeneity of 97% (discharge).

Five studies were found that used triglycerides as a variable (Figure 3B). Totaling 237 patients (111 patients in the control group and 126 patients in the intervention group), a significant difference was found between the groups [TE 1.36 (CI: 0.26, 2.44)], with a heterogeneity of 92% (discharge).

DISCUSSION

С

The present study verified in the scientific literature whether strength training and aerobic training (combined or isolated) promote improvements in body composition, total cholesterol, and triglycerides in HIV patients. It encompassed 10 studies, compiling a sample of 572 participants with an average age of 41.9 years and an average infection time of 8.8 years, of which 62% were women. The interventions were carried out for periods between 12 and 48 weeks, showing no effectiveness in mitigating the increase in fat.

Despite the potential of physical exercise programs to positively alter body composition, there was no significant effect on the variables body fat [TE0.68 (CI: -0.71, 2.07)], lean mass [TE0.35 (CI: -0.01, 0.71)], BMI [TE 0.44 (IC: -0.85, 1.72)], WHR [TE 0.41 (IC: -0.11, 0.93)]. In addition, there was no change in total cholesterol [TE -0.05 (CI: -1.94, 1.84)]. The triglyceride variable showed a significant change of great magnitude (TE> 1) in favor of the intervention group [TE 1.36 (CI: 0.26, 2.44)].

Although most variables have no significant effect on the meta-analytical analysis, some important considerations about the results should be made considering the individual data from these studies. Regarding body fat, Terry, and collaborators¹⁷, Mutimura and collaborators²⁴ and Ogalha and collaborators²⁷ found significant decreases in percentage terms, in the order of 18.5%, 5.1%, and 7.4 % respectively, which may reflect clinical improvements. Cavalcanti et al.³¹ pointed out that the minimum detectable difference (MDD) for body fat measured by dual emission X-ray absorptiometry⁸ is 4.3% or 628 grams for HIV + individuals with lipodystrophy. An MDD means the smallest difference in individual scores that represent true changes that go beyond the standard error of the measurement. Thus, studies that include scores within this range may represent clinical improvements for individuals. In addition, the differences between the results obtained may result from the evaluation method used. Studies that used DEXA to assess body



fat^{16, 18, 30} showed variations in the range of 20% to 0.7% for this variable. Such variations may result from the type of sample, since in some studies^{16-18, 25, 29, 30} it was composed only of men or women, while in the other selected works they were of a mixed sample. Studies indicate that women have a higher proportion of fat mass and a greater amount of fat in the subcutaneous compartments compared to men³², which may explain part of this difference between studies. Regarding the studies that used the method of summation of skinfold thickness^{17, 24, 25}, although it is a doubly indirect method for estimating body fat, it is validated and very useful in research or in patient monitoring services. where there is no imaging equipment33.

In fact, Florindo et al.³³, in a study to validate a method of estimating body fat in HIV / AIDS patients by comparing the values provided by DEXA with the sum of the thickness of skinfolds and body circumferences, found positive correlation ($r \ge 0.80$) for total subcutaneous fat (by summing the thickness of 7 folds), central subcutaneous fat (summing up the thickness of 4 folds) and subcutaneous limb fat (summing up the thickness of 3 folds) finding also correlation between waist circumference with subcutaneous and total abdomen fat, and waist / hip ratio and the sum of subcutaneous fat folds in the central region with total abdomen fat.

Regarding the waist-to-hip ratio (RCQ), Terry and collaborators¹⁷, Mutimura and collaborators^{24, 25}, and Roos and collaborators²⁸, showed decreases of 1.1%, 10.1%, 10.1% and 1.3%, respectively, which are important because WHR has a positive correlation ($r \ge 80$) with total abdomen fat, which accumulation may represent an increase in cardiovascular risk in addition to being associated with hyperinsulinemia³⁴.

As for waist circumference, Mutimura and collaborators^{24,} ²⁵, and Dolan and collaborators¹⁸, showed significant decreases of 7.9%, 7.8% and 0.8% respectively, while Roos and collaborators²⁸, showed increases of 0.7%. Regarding BMI, an interesting fact is that the study by Hamid et al.²⁹, even with increases, has a BMI below that found in other studies^{35, 36} and according to the recommendations established by the World Health Organization (WHO)³⁷.

Regarding the triglyceride variable, there were reductions in favor of the physical exercise group of up to 16%, which is the most relevant finding in this study. The potential for exercise to reduce triglycerides regardless of significant weight change has already been demonstrated in a recent meta-analysis, but the benefits are substantially greater when weight loss occurs³⁸. Consequently, although physical exercise alone can be effective in reducing triglycerides, the greatest benefits occur when exercise interventions contribute to weight loss, which indicates that other strategies combined with exercise, such as restriction of dietary energy, can be important, and future studies should verify this issue in patients with the HIV virus. In addition, the use of protease inhibitors decreases the expression of adipocyte markers, which may cause an increase in circulating triglycerides³⁹.

CONCLUSION

Based on the evidence presented, we point out that strength exercise and aerobic exercise, performed in an isolated or combined manner, were not effective in changing variables related to body composition and total cholesterol in patients with HIV, however an important change was seen in the variable triglycerides.

REFERENCES

- Pavlova-McCalla E, Trepka MJ, Ramirez G, Niyonsenga T. Socioeconomic status and survival of people with human immunodeficiency virus infection before and after the introduction of highly active antiretroviral therapy: A systematic literature review. Journal of AIDS & clinical research. 2012;3(6).
- 2. van Zyl G, Bale MJ, Kearney MF. HIV evolution and diversity in ART-treated patients. 2018;15(1):14.
- Lu DY, Wu HY, Yarla NS, Xu B, Ding J, Lu TR. HAART in HIV/ AIDS Treatments: Future Trends. Infectious disorders drug targets. 2018;18(1):15-22.
- Koch CD, Gladwin MT, Freeman BA, Lundberg JO, Weitzberg E, Morris A. Enterosalivary nitrate metabolism and the microbiome: Intersection of microbial metabolism, nitric oxide and diet in cardiac and pulmonary vascular health. Free Radical Biology and Medicine. 2017;105:48-67.
- 5. Tate T, Willig AL, Willig JH, Raper JL, Moneyham L, Kempf MC, et al. HIV infection and obesity: where did all the wasting go? Antiviral Therapy. 2012;17(7):1281-9.
- Grant PM, Kitch D, McComsey GA, Collier AC, Bartali B, Koletar SL, et al. Long-term body composition changes in antiretroviral-treated HIV-infected individuals. Aids. 2016;30(18):2805-13.
- Erlandson KM, Lake JE. Fat Matters: Understanding the Role of Adipose Tissue in Health in HIV Infection. Curr HIV/ AIDS Rep. 2016;13(1):20-30.
- 8. Gelpi M, Afzal S, Lundgren J, Ronit A, Roen A, Mocroft A, et al. Higher Risk of Abdominal Obesity, Elevated Low-Density Lipoprotein Cholesterol, and Hypertriglyceridemia, but not of Hypertension, in People Living With Human Immunodeficiency Virus (HIV): Results From the Copenhagen Comorbidity in HIV Infection Study. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018;67(4):579-86.
- 9. Alikhani A, Morin H, Matte S, Alikhani P, Tremblay C, Durand M. Association between lipodystrophy and length of



exposure to ARTs in adult HIV-1 infected patients in Montreal. BMC infectious diseases. 2019;19(1):820.

- Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140(11):E596-E646.
- 11. Sato F, Maeda N, Yamada T, Namazui H, Fukuda S, Natsukawa T, et al. Association of Epicardial, Visceral, and Subcutaneous Fat With Cardiometabolic Diseases. Circulation journal : official journal of the Japanese Circulation Society. 2018;82(2):502-8.
- Keating SE, Hackett DA, Parker HM, Way KL, O'Connor HT, Sainsbury A, et al. Effect of resistance training on liver fat and visceral adiposity in adults with obesity: A randomized controlled trial. Hepatology research : the official journal of the Japan Society of Hepatology. 2017;47(7):622-31.
- 13. Ashton RE, Tew GA. Effects of short-term, medium-term and long-term resistance exercise training on cardiometabolic health outcomes in adults: systematic review with meta-analysis. 2020;54(6):341-8.
- Grgic J, Schoenfeld BJ, Davies TB, Lazinica B, Krieger JW, Pedisic Z. Effect of Resistance Training Frequency on Gains in Muscular Strength: A Systematic Review and Meta-Analysis. Sports medicine. 2018;48(5):1207-20.
- Panissa VLG, Fukuda DH, de Oliveira FP, Parmezzani SS, Campos EZ, Rossi FE, et al. Maximum Strength Development and Volume-Load during Concurrent High Intensity Intermittent Training Plus Strength or Strength-Only Training. Journal of sports science & medicine. 2018;17(4):623-32.
- 16. Lindegaard B, Hansen T, Hvid T, van Hall G, Plomgaard P, Ditlevsen S, et al. The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. The Journal of clinical endocrinology and metabolism. 2008;93(10):3860-9.
- Terry L, Sprinz E, Stein R, Medeiros NB, Oliveira J, Ribeiro JP. Exercise training in HIV-1-infected individuals with dyslipidemia and lipodystrophy. Medicine and science in sports and exercise. 2006;38(3):411-7.
- Dolan SE, Frontera W, Librizzi J, Ljungquist K, Juan S, Dorman R, et al. Effects of a supervised home-based aerobic and progressive resistance training regimen in women infected with human immunodeficiency virus: a randomized trial. Archives of internal medicine. 2006;166(11):1225-31.
- **19.** Akobeng AK. Principles of evidence based medicine. Archives of disease in childhood. 2005;90(8):837-40.
- Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled clinical trials. 1996;17(1):1-12.

- Cumpston M, Li T, Page MJ, Chandler J, Welch VA, Higgins JP, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane database of systematic reviews. 2019;10:Ed000142.
- De Carvalho A, Silva V, Grande A. Avaliação do risco de viés de ensaios clínicos randomizados pela ferramenta da colaboração Cochrane. Diagn Tratamento. 2013;18(1):38-44.
- 23. Zorzela L, Loke YK, Ioannidis JP, Golder S, Santaguida P, Altman DG, et al. PRISMA harms checklist: improving harms reporting in systematic reviews. Bmj. 2016;352:i157.
- 24. Mutimura E, Crowther NJ, Cade TW, Yarasheski KE, Stewart A. Exercise training reduces central adiposity and improves metabolic indices in HAART-treated HIV-positive subjects in Rwanda: a randomized controlled trial. AIDS Res Hum Retroviruses. 2008;24(1):15-23.
- **25.** Mutimura E, Stewart A, Crowther NJ, Yarasheski KE, Cade WT. The effects of exercise training on quality of life in HAART-treated HIV-positive Rwandan subjects with body fat redistribution. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2008;17(3):377-85.
- 26. Balasubramanyam A, Coraza I, Smith EO, Scott LW, Patel P, Iyer D, et al. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoad-iponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. The Journal of clinical endocrinology and metabolism. 2011;96(7):2236-47.
- 27. Ogalha C, Luz E, Sampaio E, Souza R, Zarife A, Neto MG, et al. A randomized, clinical trial to evaluate the impact of regular physical activity on the quality of life, body morphology and metabolic parameters of patients with AIDS in Salvador, Brazil. Journal of acquired immune deficiency syndromes (1999). 2011;57 Suppl 3:S179-85.
- Roos R, Myezwa H, van Aswegen H, Musenge E. Effects of an education and home-based pedometer walking program on ischemic heart disease risk factors in people infected with HIV: a randomized trial. Journal of acquired immune deficiency syndromes (1999). 2014;67(3):268-76.
- 29. Hamid MSA, Rajah SJJ. Effects of progressive resistance exercises on quality of life, body composition and muscle strength in patients with HIV. Sains Malaysiana. 2015;44(10):1473-9.
- Yarasheski KE, Cade WT, Overton ET, Mondy KE, Hubert S, Laciny E, et al. Exercise training augments the peripheral insulin-sensitizing effects of pioglitazone in HIV-infected adults with insulin resistance and central adiposity. American Journal of Physiology-Endocrinology and Metabolism. 2011;300(1):E243-E51.
- 31. Cavalcanti RB, Cheung AM, Raboud J, Walmsley S. Reproducibility of DXA estimations of body fat in HIV lipodystro



phy: implications for clinical research. Journal of Clinical Densitometry. 2005;8(3):293-7.

- 32. Kotler DP, Thea DM, Heo M, Allison DB, Engelson ES, Wang J, et al. Relative influences of sex, race, environment, and HIV infection on body composition in adults. The American journal of clinical nutrition. 1999;69(3):432-9.
- Florindo AA, Latorre MdRDdO, Santos ECMd, Borelli A, Rocha MdS, Segurado AAC. Validação de métodos de estimativa da gordura corporal em portadores do HIV/Aids. Revista de saude publica. 2004;38:643-9.
- Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. New England Journal of Medicine. 2005;352(1):48-62.
- 35. Soares TCM. HIV/AIDS e estilo de vida: parâmetros imunológicos, virológicos, síndrome lipodistrófica e sua relação com a prática de exercícios. 2012.

- 36. Florindo AA. Atividade física habitual e sua relação com a composição corporal em adultos portadores do HIV/Aids em uso de terapia anti-retroviral de alta atividade. 2003.
- 37. Organization WH. Preventing and managing the global epidemic. WHO Technical Report Series. 1998;894.
- 38. Sargeant JA, Gray LJ, Bodicoat DH, Willis SA, Stensel DJ, Nimmo MA, et al. The effect of exercise training on intrahepatic triglyceride and hepatic insulin sensitivity: a systematic review and meta-analysis. 2018;19(10):1446-59.
- 39. Nduka C, Sarki A, Uthman O, Stranges S. Impact of antiretroviral therapy on serum lipoprotein levels and dyslipidemias: a systematic review and meta-analysis. International journal of cardiology. 2015;199:307-18.

